Product

2-Hydroxybenzylamine

Aliases

2-HOBA

3 clinical trials

4 indications

Indication

Atrial Fibrillation

Indication

Familial Hypercholesterolemia

Indication

Alzheimer's disease

Indication

Mild Cognitive Impairment

Clinical trial

2-Hydroxybenzylamine (2-HOBA) to Prevent Early Recurrence of Atrial Fibrillation After Catheter- Based Ablation

Status: Active (not recruiting), Estimated PCD: 2024-06-16

Clinical trial

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

Status: Recruiting, Estimated PCD: 2025-07-01

Clinical trial

2-Hydroxybenzylamine (2-HOBA) Phase 1b/2a Proof-of Concept, Dose-Finding, Biomarker Study in Early Alzheimer's Patients

Status: Not yet recruiting, Estimated PCD: 2027-06-30